Diabetes: Lowering serum uric acid levels to prevent kidney failure

Nature Reviews Nephrology

Volumn 7, Issue 9, 2011, Pages 495-496

  Doria, Alessandro ^a   Krolewski, Andrzej S ^a  

^a JOSLIN DIABETES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIURETIC AGENT; URIC ACID; XANTHINE OXIDASE;

DENMARK; DIABETES MELLITUS; DIABETIC PATIENT; HEMODYNAMIC MONITORING; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MICROALBUMINURIA; MORTALITY; OBSERVATIONAL STUDY; OXIDATIVE STRESS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SERUM; URIC ACID BLOOD LEVEL;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; DIABETIC NEPHROPATHIES; HUMANS; HYPERURICEMIA; KIDNEY FAILURE, CHRONIC; LOSARTAN; URIC ACID;

EID: 80052270704     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2011.107     Document Type: Review

References (10)

1. Rosolowsky, E. T. et al. Risk for ESRD in type 1 diabetes remains high despite renoprotection. J. Am. Soc. Nephrol. 22, 545-553 (2011).
2. Ficociello, L. H. et al. High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: Results of a 6-year follow-up. Diabetes Care 33, 1337-1343 (2010).
3. Jalal, D. I. et al. Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: Findings from the Coronary Artery Calcification in Type 1 Diabetes study. Nephrol. Dial. Transplant. 25, 1865-1869 (2010).
4. Hovind, P., Rossing, P., Tarnow, L., Johnson, R. J. & Parving, H. H. Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: An inception cohort study. Diabetes 58, 1668-1671 (2009).
5. Kang, D. H. et al. A role for uric acid in the progression of renal disease. J. Am. Soc. Nephrol. 13, 2888-2897 (2002).
6. Johnson, R. J. et al. Essential hypertension, progressive renal disease, and uric acid: A pathogenetic link? J. Am. Soc. Nephrol. 16, 1909-1919 (2005). (Pubitemid 41716421)
7. Goicoechea, M. et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin. J. Am. Soc. Nephrol. 5, 1388-1393 (2010).
8. Siu, Y. P., Leung, K. T., Tong, M. K. & Kwan, T. H. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am. J. Kidney Dis. 47, 51-59 (2006). (Pubitemid 41828266)
9. Miao, Y. et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: A post hoc analysis of the Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus With the Angiotensin II Antagonist Losartan Trial. Hypertension 58, 2-7 (2011).
10. Becker, M. A. et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N. Engl. J. Med. 353, 2450-2461 (2005). (Pubitemid 41781828)